Somewhere right now a 73-year-old ophthalmologist in the suburbs of New York is running a practice he built over 25 years. Strong revenue, loyal patients, and staff who've been there for a decade. He has no idea what happens to any of it when he's done.
He's not looking to sell to private equity, especially because he watched what happened to his colleague's practice after a PE group acquired it: volume targets, staff turnover, patients complaining that nobody knows their name anymore. He's not interested in that exit and wants someone who'll take care of what he built.
That conversation is happening across thousands of practices right now, and for a capital allocator who understands what it actually represents, it's one of the most compelling private investment opportunities in the lower middle market. The data makes it visible in a way it has never been before.
The Deal Flow by the Numbers
The reason most investors have never looked at ophthalmology practice acquisitions is that the deal flow was never quantified at the provider level. You could read about aging physicians and workforce shortages in a healthcare journal, but you couldn't see exactly how many practices were approaching transition, in which geographies, subspecialties, and on what timeline.
That data now exists.
The national picture starts with roughly 9,000 solo ophthalmologists currently practicing in the United States, and more than 5,700 of them are 55 or older. Using age-based exit probability modeling across the full solo practitioner population, the projected retirement curve is steep: approximately 3,143 will have exited by 2027, 4,332 by 2030, 5,093 by 2033, and 5,554 by 2035. That last number represents more than 60% of the current solo practitioner pool exiting over a single decade.
This is a concentrated wave hitting a specific segment of a specific specialty over a defined window, and it isn't distributed evenly across the country.
Where the Deals Are Concentrated
The geographic distribution of this wave matters as much as the aggregate number. California leads with approximately 800 solo practitioners aged 55 or older, New York follows at 702, Florida sits at 488, Texas at 354, and New Jersey at 268. Those 5 states alone account for nearly half of every senior solo ophthalmologist in the country.
The more interesting number for an investor thinking about deployment is the Northeast corridor. New York, New Jersey, and Connecticut combined represent a significant concentration of senior solo ophthalmologists in a geographic footprint you can drive across in 3 hours. These aren't rural practitioners spread across vast distances. They're concentrated in suburbs and mid-size cities where patient panels are large, referral relationships are deep, and the practices themselves represent meaningful annual revenue with established cash flow.
That density matters for 2 reasons. First, an operator with a presence in the tri-state area can source and execute acquisitions without building a national infrastructure because the deal flow is local and accessible. Second, the succession wave in this geography will hit multiple practices in the same referral networks at roughly the same time, which creates consolidation opportunities that compound rather than compete with each other.
The Vintage Cohort That Matters Most
Not all of the 5,700 senior solo practitioners are equally positioned to transact in the next 3 to 5 years. The cohort that represents the most actionable near-term deal flow is the 15 to 20 year practice vintage, physicians who opened their doors between roughly 2005 and 2011 and have been running their practices for close to 2 decades.
Nationally, this cohort contains thousands of solo practitioners with significant concentration in the Northeast corridor. These are physicians who are deep enough into their careers that retirement is a real near-term conversation, but whose practices are young enough to have modern infrastructure, current patient panels, and operational relevance. Some are in their late 50s weighing the next 5 years. Others are in their 70s and have been quietly looking for the right buyer for longer than they'd admit. All of them built something that works and are now facing the same problem: nobody to hand it to.
The Pricing Environment
Acquisition multiples for solo ophthalmology practices below the threshold where PE platforms allocate attention currently reflect the thin buyer market rather than the underlying cash flow quality of the asset.
The buyer pool for these practices is limited to other physicians, small regional groups, and a handful of smaller MSO operators. Large PE platforms ignore the segment because the deal size doesn't justify their overhead, and the absence of competitive bidding keeps pricing rational for acquirers who have the infrastructure to operate at this scale. A refractive surgery practice with strong cash-pay revenue and a premium procedure mix commands a higher multiple than a general ophthalmology practice with heavier Medicare exposure, but even at the higher end of the range, the multiples are modest relative to what comparable cash-flowing businesses trade for in other sectors.
As the succession wave accelerates and more capital becomes aware of the opportunity, that pricing environment will tighten. The practices that change hands in the next 3 years will do so at better multiples than the ones that come to market in 2029 after the opportunity has become obvious to a broader set of allocators.
What the Investment Looks Like in Practice
An acquisition in this segment typically involves a hybrid capital structure combining equity and a promissory note with defined repayment terms and structural downside protection. The equity participates in the MSO entity that operates the practice and holds the management contract, and the note begins servicing from day one of operations.
A practice generating strong annual revenue, acquired at a multiple reflecting the thin buyer market, produces enough net cash flow to cover debt service with meaningful coverage while generating equity distributions from the MSO margin. The investor isn't waiting for an exit event to see returns because the cash flow starts immediately and the equity compounds as the platform expands.
The platform expansion is where the investment thesis becomes more interesting than any single deal. Each acquisition adds to a portfolio of cash-flowing practices in overlapping referral geographies. The operational infrastructure built for the first acquisition, including billing, staffing, compliance, and the physician pipeline, becomes more efficient with each subsequent practice. The marginal cost of adding a practice to an established platform is lower than the cost of building the first one, which means returns improve as the portfolio grows.
The return for an investor in this structure doesn't depend on finding a buyer at the end of a fund cycle. Distributions come from operations and equity appreciates as the platform matures, and if a liquidity event comes, it comes from a position of operational strength rather than urgency.
The Window
The conditions that make this opportunity attractive, including motivated sellers, rational pricing, limited competition, and concentrated deal flow, are a function of a specific moment in the succession cycle. That moment is now and it lasts approximately 5 to 7 more years before the wave crests and the market adjusts.
Capital that enters the ophthalmology acquisition market in the next 3 years is entering at the point of maximum deal flow, minimum competition, and most favorable pricing. Capital that waits will enter a market that looks increasingly like every other healthcare services consolidation play: crowded, expensive, and dominated by platforms that moved early.
The data that describes this opportunity wasn't available 5 years ago because the succession wave hadn't yet become visible at the provider level. It's visible now because the infrastructure to quantify it exists, and the opportunity is real.
If you're a capital allocator who has been looking for private assets with real cash flow, structural downside protection, and a demographic tailwind that doesn't depend on the economy, this is the conversation worth having before the window closes.
This article is for general educational purposes and is not investment advice.
Verdira is a healthcare acquisition platform focused on ophthalmology practices, built around physician ownership, transparent structure, and no volume quotas. If you're looking for a different model, or you know a colleague who is, we're open to thoughtful conversations.
Contact info@verdira.com | 307-381-3734 | verdira.com
